Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 709 participants.

Also called NCT04849000

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 709 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04849000
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04849000. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-23 (actual); primary completion 2022-06-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage
Condition
Primary Hypercholesterolemia
Condition
Mixed Hyperlipemia
Intervention (Drug)
SHR-1209
Intervention (Drug)
SHR-1209 Placebo
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04849000
Content hash
3cbd5a0091a5801a303a43536e17a58ea1cadc4e75a9557a38213d2162f55d68